Clinical features and outcomes of new daily persistent headache in patients in China and comparison with medication-overuse headache: A double-center retrospective study

Huanxian Liu
Department of Neurology, the first medical center, the Chinese PLA General Hospital

Ye Ran
Department of Neurology, the first medical center, the Chinese PLA General Hospital

Liang Dang
Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Ruirui Yang
Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Shuping Sun
Department of Neurology, the first medical center, the Chinese PLA General Hospital

Meichen Zhang
Department of Neurology, Beijing Jingmei Group General Hospital

Ke Li
Department of Neurology, the first medical center, the Chinese PLA General Hospital

Chunfu Chen
Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Zhao Dong (dong_zhaozhao@126.com)
Chinese PLA General Hospital  https://orcid.org/0000-0002-4581-2569

Shengyuan Yu
Department of Neurology, the first medical center, the Chinese PLA General Hospital

Research article

Keywords: New daily persistent headache, medication overuse headache, clinical features, prognosis

DOI: https://doi.org/10.21203/rs.3.rs-103153/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: This study examined the clinical features and outcomes of NDPH patients and comparison with medication-overuse headache (MOH) in mainland China.

Methods: This retrospective study observed patients with NDPH and medication-overuse headache (MOH) visiting two outpatient clinics between November 2011 and December 2019. Clinical information was collected and all patients were followed by telephone.

Results: The study recruited 73 NDPH and 638 MOH patients. The NDPH patients included 39 males (53.4%) and 34 females (46.6%), with an average age of 37.4 years and average headache duration of 10.6 years. Headache-precipitating factors included infection (15.1%) and stress (30.1%). Compared to MOH patients, NDPH patients had a male predominance (53.4% vs. 22.6%, \( p < 0.001 \)), younger age of CDH onset (26.7±12.3 vs. 41.4±11.3 years, \( p < 0.001 \)), and longer duration of CDH (10.6±11.8 vs. 6.1±6.2 years, \( p = 0.023 \)). Of the 62 NDPH patients followed up for 31 months, on average, therapeutic responses were more effective in NDPH patients with trigger factors than in those without trigger factors (71.4% vs. 32.4%; \( p = 0.002 \)); the odds ratio (OR) of an effective outcome was 5.25 (1.73-17.84, \( p = 0.005 \)).

Conclusions: NDPH is significantly different from MOH, with a male predominance, younger age of CDH onset, and longer duration of CDH. The presence of trigger factors is an independent predictor of better treatment effect in NDPH patients.

Introduction

New daily persistent headache (NDPH) is a relatively rare primary headache characterized by daily onset and a lack of quick remission; NDPH does not have a specific treatment, and patients invariably recall and can accurately describe its onset [1]. NDPH is also a disabling disease that may affect the quality of life of individuals and threaten public health [2]. According to the International Classification of Headache Disorders 3rd edition (ICHD-3), the diagnostic criteria for NDPH include the following: A. persistent headache fulfilling criteria B and C; B. distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours; C. present for > 3 months; D. not better accounted for by another ICHD-3 diagnosis [1]. As the most refractory headache disorder, NDPH accounts for 1.7–10.8% of cases of chronic daily headache (CDH) in adult patients [3, 4], and data from China represent 3.6% of patients with CDH [5]. Although some countries and regions have summarized the clinical features, trigger factors and prognosis of NDPH, detailed data of NDPH from mainland China are lacking.

Medication-overuse headache (MOH) occurs in patients with preexisting primary headache due to frequent and long-term use of acute or symptomatic headache medication, which leads to aggravated headache or the emergence of new headache types [1]. MOH accounts for 11–70% of the patients with CDH [6], and epidemiology data from China accounts for 60% of patients with CDH [7]. Although there was a previous study comparing chronic migraine (CM) with NDPH [8], the enrolled participants were children and adolescents, and there is a lack of studies in adult patients. NDPH and MOH are two different types of headaches that have significantly different prevalence in CDH. Basically, NDPH is a rare type of CDH, while MOH is the most common type [5]. Comparing NDPH with MOH may provide some novel information about clinical features of NDPH. Therefore, the present study aimed to provide comprehensive data on the clinical features and outcomes of NDPH patients and comparison MOH in mainland China. Additionally, the predictor factors for treatment efficacy are also involved.

Subjects And Methods

Study design
This was a retrospective analysis of patient medical records and a phone interview was used for follow-up. Patients who were admitted to the neurology outpatient clinics of Chinese PLA General Hospital (Professor Zhao Dong) and Shandong Provincial Hospital (Professor Chunfu Chen) between November 2011 and December 2019 and who diagnosed with NDPH were recruited. MOH patients visiting the two clinics during the same period were also involved. All enrolled patients were re-examined by another headache specialist (Professor Shengyuan Yu). Patients with MOH met the diagnostic criteria of MOH according to ICHD-3 criteria. The inclusion criteria for NDPH were as follows: (1) met the NDPH diagnostic criteria according to ICHD-2,3; and (2) underwent neuroimaging (MRI with gadolinium) and fundoscopy examination. The exclusion criteria for NDPH were as follows: (1) increasing headache frequency prior to persistent headache; (2) possible secondary headache, such as headache after trauma and headache after intracranial diseases; (3) abnormal neuroimaging, which can account for persistent headache; and (4) papilledema. All headache patients have been recommended to keep a headache diary and instructed to how to correctly record.

The patients who were unconnected and treated for less than 3 months were not included in the analysis of treatment responses and prognostic factors. The clinical response to drug-based treatment was assessed by the patients themselves based on reducing the number of headache days and alleviating headache intensity. Treatment outcome was defined subjectively as “effective” when a patient felt >50% improved and “not effective” when improvement was <50% or the patient was unchanged. NDPH patients were divided into two group according to the treatment outcome. To assess the relationship between the treatment outcome and headache duration, the patients were categorized into two groups: NDPH (6-24 months) and NDPH (>24 months). Another demographic and clinical characteristics factors were included in the analysis.

This study was approved by the ethics committee of Chinese PLA General Hospital and Shandong Provincial Hospital. Due to the retrospective nature of the study, according to the Declaration of Helsinki of the World Medical Association, verbal informed consent was obtained from the all patients before being included in the study.

Data collection

All of the patients’ medical records collected via a unified chart, which included the following information: (1) demographic characteristics (sex, age, age of CDH onset and education level); (2) the clinical features of the headache (main headache site, severity, frequency, associated feature, pain character and aggravation after activity); (3) the type, frequency and duration of pain reliever use; and (4) comorbid diseases, such as anxiety and depression based on the GAD-7 and PHQ-9 scales. Headache severity was assessed based on the visual analog scale (VAS).

Statistical analysis

All continuous measurements conforming to a normal distribution are presented as the mean ± standard deviation (SD). Nonnormally distributed continuous variables are indicated with medians and quartiles. Categorical variables are presented as rates. The chi-square test or Fisher’s exact test was performed for count data, and the Wilcoxon test was performed for nonnormally distributed continuous variables. In order to clarify whether a variable is an independent factor, the variable with a $p < 0.05$ was included in nonconditional logistic regression analysis. The data were analyzed using SPSS for Windows, Version 21.0 (IBM Company, Chicago, Illinois in the United States); $p < 0.05$ was considered indicative of statistical significance.

Results

A total of 76 patients with a diagnosis of NDPH initially, including 53 cases from the Chinese PLA General Hospital and 23 cases from Shandong Provincial Hospital, were enrolled. Three patients were excluded because of incomplete information. Finally, a total of 73 patients were recruited in this retrospective study (Figure 1). A total of 55 (75.3%) patients fulfilled the
NDPH diagnostic criteria of ICHD-2. Moreover, we recruited 638 patients with a diagnosis of MOH during the same period, including 518 cases from the Chinese PLA General Hospital and 120 cases from Shandong Provincial Hospital.

**Demography of NDPH patients**

The demographic and clinical characteristics of NDPH are summarized in Table 1. Among all NDPH patients, 39 were male (53.4%), and 34 were female (46.6%), with an average age of 37.4 ± 14.3 years (14-66 years). The average age of headache onset was 26.7±12.3 years (13-58 years). The average duration of headache was 10.6±11.8 years (0.5-51 years). The peak age of onset was 11 to 20 years for males and 21 to 30 years for females.

**Clinical characteristics of NDPH**

All patients distinct and clearly remembered onset day. The headache developed bilaterally in 58 (79.5%) patients and unilaterally in 15 (20.5%), and its nature was throbbing for 7 (9.6%) and non-throbbing for 77 (90.4%). The average pain intensity on VAS was 5.3±2.0. Among all NDPH patients, 32 (43.8%) patients were aggravated by routine physical activities. Accompanying symptoms included phonophobia in 12 (16.4%) patients, photophobia in 9 (12.3%) patients, nausea in 14 (19.2%) patients and vomiting in 1 (1.4%) patient. Regarding the precipitating factor of the headache, 40 (54.8%) patients had no trigger factors, 11 (15.1%) patients had an infection (respiratory infection), and 22 (30.1%) patients had stressful life events. Only one NDPH patient (1.4%) reported migraine history. Among all NDPH patients, 38 (52.1%) had generalized anxiety disorder (GAD-7 score ≥10), and 27 (36.9%) had depression (PHQ-9 ≥13).

**Comparison between NDPH and MOH**

The demographic and clinical characteristics of patients with NDPH were compared to those of patients with MOH (Figure 2, Figure 3). There were significant differences in sex, age at onset of CDH, duration of CDH, educational level and pain intensity between the NDPH and MOH patients (Table 2). The proportion of males among the NDPH patients (39/73, 53.4%) was significantly higher than that among the MOH patients (144/638, 22.6%). The age of onset of CDH of the NDPH patients (26.7±12.3) was significantly younger than that of the MOH patients (41.4±11.3). However, the duration of CDH of the NDPH patients (10.6±11.8) was significantly longer than that of the MOH patients (6.1±6.2). The average pain intensity on the VAS for the NDPH patients (5.3±2.0) was significantly lower than that for the MOH patients (6.9±1.6). In addition, the educational level of NDPH patients (54/73, 74.0%) was significantly higher than that of MOH patients (293/638, 45.9%).

**Treatment and prognosis**

Among 73 NDPH patients, seven patients failed to be contacted, and four patients were treated for less than 3 months. In total, 62 NDPH patients completed more than 3 months of follow-up by telephone (Figure 1). The average follow-up was 31 months. Of these, 31 demonstrated the effectiveness of treatment, and 31 demonstrated unsatisfactory treatment. We compared the relationship between the therapeutic responses of NDPH patients and their demographic and clinical characteristics (Table 3). The therapeutic responses were more effective in NDPH patients with trigger factors than in those without trigger factors (71.4% vs 32.4%; p=0.002). The NDPH patients with stress-related trigger factors had better therapeutic responses than those with infection-related trigger factors (85.0% vs 37.5%; p=0.002) (Table 4). No significant differences in sex, pain intensity, headache duration, headache characteristics or education level were observed between patients who had effective outcomes and those who had no effective outcomes (Figure 4). NDPH with trigger factors was included in the logistic regression analysis, and the odds ratio (OR) for an effective outcome was 5.25 (1.73-17.84, p=0.005) (Figure 4).

**Discussion**
This study assessed the clinical features of NDPH, the effectiveness of drug-based treatment and the risk factors for treatment effects in the largest sample in China mainland to date. We found that there were significant differences in demographic and clinical characteristics between NDPH and MOH patients. The presence of trigger factors is an independent factor for the treatment effect of NDPH patients. The patients with stress-related trigger factors had a better outcome than those with infection-related trigger factors.

**Clinical features of NDPH**

Our study revealed a male predominance (female/male=0.9:1), which is nearly similar to data from India (0.8:1) [9] but contrary to data from the USA (2:1) [10]. The mean age at onset for NDPH is 26.7 years, which is similar to that reported by Uniyal et al. (28.24 years) [9] (Table 5). The clinical characteristics of the NDPH in our study were bilateral localization, non-throbbing nature, and a typical lack of association with nausea and vomiting; these characteristics were similar to those of chronic tension type headache in many cases. However, other summarized literature demonstrated the presence of migraine-like features in NDPH patients, with a proportion of 35-64.1%(8, 9, 11-13). NDPH typically occur in individuals without a prior headache history (1). In our study, there was one patient (1.4%) had headache history. However, other summarized literature demonstrated the presence of prior headache history in NDPH patients, with a proportion of 7-54%(4, 12). In terms of comorbid mental disorders in NDPH, the majority of our patients had anxiety (38/73, 52.1%) and depressive (27/73, 36.9%) symptoms. Uniyal et al. even reported a more common prevalence of anxiety (92.7%) and depression (89.1%) in their patients [9]. The causal relationship between anxiety, depression and chronic headaches or vice versa is still unclear [9] (Table 5). None of the patients had medication overuse in our study. However, Prakash et al. and Kung et al. reported medication overuse in 13% and 8.7% of their patients, respectively [12, 14]. Moreover, an observational study by Peng et al. also reported that NDPH patients had a higher proportion (34.8%) of medication overuse [13]. We consider the following possible reasons for these findings. First, most of the patients in our cohort showed headache characteristics similar to those of tension-type headaches, which means that the headache is mild to moderate, so analgesics may not be necessary. Reidy et al. also found that youth with NDPH were less likely to have medication overuse compared to youth with CM [8]. Another reason may be that even when analgesics were used, most of them were not effective for NDPH patients.

Infection and stress events are the two main trigger factors of NDPH [10], while the proportion varies among different studies. Most of our patients (22/73, 30.1%) complained that their self-reported triggering events were related to stressful events, which is higher than the corresponding data reported by Uniyal et al. (5/55, 9.1%) [9] and Rosen (9/97, 9%) [10]. Another factor in our study was infection (15.1%). Some authors have found that some NDPH patients who had been infected with viruses before headache, such as Epstein-Barr virus (EBV) [15], herpes simplex virus (HSV) [16], cytomegalovirus (CMV) [16], and dengue virus (DENV) [17], speculated that chronic central nervous system inflammation may be involved in the pathophysiological mechanism of NDPH [2]. However, only a few patients suffered NDPH after infections, which suggests that some unknown mechanism needs to be further explored. Other trigger factors reported by other studies, such as surgery procedures with intubation, withdrawal from SSRIs, human papilloma virus vaccination [2, 10], and Valsalva event [18], were absent in our study.

**Comparison between NDPH and MOH**

We found several significant differences in sex predominance, age at onset of CDH, duration of CDH, educational level and pain intensity between NDPH and MOH. First, NDPH occurred more often in males than in females. The most likely reason is that primary headache diseases in general, especially migraine, are more common in women [7], and these are the main risk factors for MOH because pre-existing headache is a necessary prerequisite. Second, our study showed that NDPH patients, compared to MOH patients, had an earlier age at onset of CDH but a longer duration of CDH, which would lead to more severe disability and therefore significantly affect the individual’s quality of life. Finally, compared with MOH, NDPH patients are more likely to have a higher educational level, which has not been revealed in a previous study. The main
reason may be that MOH patients attained a lower education level [19], which is a risk factor for medication overuse in headache patients [20]. This difference needs to be confirmed in further clinical studies.

**Treatment and prognosis of NDPH**

NDPH has two subtypes: a self-limiting subtype that typically resolves within several months without therapy and a refractory subtype that is resistant to aggressive treatment regimens [1]. Vanast first found that 78% of patients became headache-free by 24 months [21] and considered NDPH a benign headache. In contrast, most subsequent studies considered it to be the most refractory to treatment and can persist for many years [2]. The likely reason for NDPH becoming more refractory was that most studies enrolled NDPH patients who had headache durations of more than 6 months [22]. In our study, the duration of headache was also more than 6 months in all patients, and the mean headache duration was 10.6 years. Our current study did not reveal that any NDPH patients self-resolved during an average follow-up of 31 months. The effective treatment rate of NDPH was 50% in our study, which was close to the effective treatment rate (67%) found by Prakash et al [12]. Although there was no significant difference in headache duration, it seems that the shorter duration has a better outcome (68.8% vs. 43.5%). Our results also supported that treatment in the early stage might improve the effectiveness of NDPH, which is similar to the result from Peng et al [13]. In our study, we found that the patients with trigger factors had a better prognosis than those without trigger factors (71.4% vs 32.4%, \( p=0.002 \), which is similar to the data from India [12]. In addition, stress is the main trigger factor of NDPH patients, and patients with stress-related trigger factors had a better outcome than those with infection-related trigger factors. We speculate that the likely reason is that these patients may handle life stress appropriately after consulting a doctor, which is helpful in reducing the frequency and severity of headaches.

**Limitations**

There are some limitations in our study. First, because the two hospitals are both tertiary care centers, the study may include selection bias. Second, because this study is a retrospective study, there could be recall bias, and the results need to be further confirmed in prospective studies.

**Conclusions**

Our study revealed that NDPH is predominant in males. NDPH patients rarely have medication overuse in China. Tension-type headache features were very common in patients with NDPH. Moreover, NDPH is significantly different from MOH in demographic and clinical characteristics, demonstrating a younger age of CDH onset, a longer duration of CDH, and a higher educational level. Additionally, the presence of trigger factors is an independent factor for the treatment effect of NDPH patients. NDPH patients with trigger factors had a better treatment outcome.

**Abbreviations**

NDPH: new daily persistent headache; ICHD-3: International Classification of Headache Disorders 3rd edition; CDH: chronic daily headache; MOH: medication overuse headache; CM: chronic migraine; VAS: visual analog scale

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the ethics committee of Chinese PLA General Hospital and Shandong Provincial Hospital.

**Consent for publication**
Due to the retrospective nature of the study, according to the Declaration of Helsinki of the World Medical Association, verbal informed consent was obtained from all patients before being included in the study.

**Availability of data and materials**

Not applicable.

**Competing interests**

The authors declared that they have no competing interests.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (grant 81771200).

**Authors’ contributions**

Huanxian Liu analyzed and interpreted the patient data, drafted the manuscript. Ye Ran drafted figures and helped to draft the manuscript. Liang Dang, Ruirui Yang, Shuping Sun, Meichen Zhang, and Ke Li helped to collect patients’ data and follow up. Chunfu Chen and Zhao Dong participated in patients’ enrollment and the design of the study. Shengyuan Yu re-examined all recruited patients and helped to design this study. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**References**

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia : an international journal of headache. 2018;38(1):1-211.

2. Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. The journal of headache and pain. 2019;20(1):80.

3. Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63(5):843-7.

4. Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia : an international journal of headache. 2004;24(11):955-9.

5. Dong Z, Di H, Dai W, Liang J, Pan M, Zhang M, et al. Application of ICHD-II criteria in a headache clinic of China. PLoS One. 2012;7(12):e50898.

6. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nature reviews Neurology. 2016;12(10):575-83.

7. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582-91.

8. Reidy BL, Riddle EJ, Powers SW, Slater SK, Kacperski J, Kabbouche MA, et al. Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache. Cephalalgia : an international journal of headache. 2020:333102420920644.

9. Uniyal R, Paliwal VK, Tripathi A. Psychiatric comorbidity in new daily persistent headache: A cross-sectional study. European journal of pain (London, England). 2017;21(6):1031-8.
10. Rozen TD. Triggering Events and New Daily Persistent Headache: Age and Gender Differences and Insights on Pathogenesis-A Clinic-Based Study. Headache. 2016;56(1):164-73.

11. Robbins MS, Grosberg BM, Napchan U, Crystal SC, Lipton RB. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010;74(17):1358-64.

12. Prakash S, Saini S, Rana KR, Mahato P. Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India. The journal of headache and pain. 2012;13(6):477-85.

13. Peng KP, Fuh JL, Yuan HK, Shia BC, Wang SJ. New daily persistent headache: should migrainous features be incorporated? Cephalalgia : an international journal of headache. 2011;31(15):1561-9.

14. Kung E, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. New daily persistent headache in the paediatric population. Cephalalgia : an international journal of headache. 2009;29(1):17-22.

15. Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet (London, England). 1987;1(8530):411-5.

16. Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2004;25 Suppl 3:S281-2.

17. de Abreu LV, Oliveira CB, Bordini CA, Valença MM. New Daily Persistent Headache Following Dengue Fever: Report of Three Cases and an Epidemiological Study. Headache. 2020;60(1):265-8.

18. Rozen TD. New daily persistent headache (NDPH) triggered by a single Valsalva event: A case series. Cephalalgia : an international journal of headache. 2019;39(6):785-91.

19. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. The Lancet Neurology. 2010;9(4):391-401.

20. Hagen K, Vatten L, Stovner LJ, Zwart JA, Krokstad S, Bovim G. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia : an international journal of headache. 2002;22(8):672-9.

21. Rozen TD. The Three T's of NDPH (How Clinical Observations Have Led to Improved Treatment Outcomes). Headache. 2019;59(8):1401-6.

22. Prakash S, Golwala P. Phantom headache: pain-memory-emotion hypothesis for chronic daily headache? The journal of headache and pain. 2011;12(3):281-6.

23. Li D and Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002; 22: 66-69.

**Tables**
Table 1. Demographic and clinical characteristics of patients with NDPH (n=73).

|                                | All  | Male            | Female          | p   |
|--------------------------------|------|-----------------|-----------------|-----|
| No. of patients                | 73   | 39 (53.4%)      | 34 (46.6%)      |     |
| Age (years, mean±SD)           | 37.4±14.3 | 38.5±11.8       | 36.6±16.8       | 0.41|
| Age at onset (years, mean±SD)  | 26.7±12.3 | 25.3±12.1       | 28.3±12.5       | 0.14|
| (years, median(quartiles))     | (23.0,16.0) | (20.0,10.0)     | (25.5,17.2)     |     |
| Duration of headache           |      |                 |                 | 0.055|
| (years, mean±SD)               | 10.6±11.8 | 12.7±12.3       | 8.3±10.8        |     |
| (years, median(quartiles))     | (5.0,17.0) | (7.0,17.5)      | (3.5,9.3)       |     |
| Education level                |      |                 |                 | 0.65|
| Low education level            | 19 (26.0%) | 11 (28.2%)      | 8 (23.5%)       |     |
| High education level           | 54 (74.0%) | 28 (71.8%)      | 26 (77.5%)      |     |
| Location of headache           |      |                 |                 | 0.080|
| Unilateral                     | 15 (20.5%) | 5 (12.8%)       | 10 (29.4%)      |     |
| Bilateral                      | 58 (79.5%) | 34 (87.2%)      | 24 (70.6%)      |     |
| Pain character                 |      |                 |                 |     |
| Non-throbbing                  | 66 (90.4%) | 37 (94.9%)      | 29 (80.6%)      |     |
| Throbbing                      | 7 (9.6%) | 2 (5.1%)        | 5 (19.4%)       |     |
| Pain intensity (VAS, mean±SD)  | 5.3±2.0 | 5.6±2.0         | 4.9±2.5         | 0.49|
| (years, median(quartiles))     | (5.0,2.0) | (6.0,2.0)       | (5.0,1.5)       |     |
| Aggravation by routine         |      |                 |                 |     |
| physical activities            | 32 (43.8%) | 17 (43.6%)      | 15 (44.1%)      |     |
| Associated feature             |      |                 |                 |     |
| Nausea                         | 14 (19.2%) | 2 (5.1%)        | 12 (35.3%)      |     |
| Vomiting                       | 1 (1.4%) | 1 (2.6%)        | 0               |     |
| Phonophobia                     | 12 (16.4%) | 6 (15.4%)       | 6 (17.6%)       |     |
| Photophobia                     | 9 (12.3%) | 5 (12.8%)       | 4 (11.8%)       |     |
| Psychiatric co-morbidities     |      |                 |                 | 0.66|
| Anxiety (GAD-7 ≥10)            | 38 (52.1%) | 19 (51.4%)      | 19 (55.9%)      |     |
| Depression (PHQ-9 ≥13)         | 27 (36.9%) | 15 (41.1%)      | 12 (35.3%)      |     |
| Triggering factors             |      |                 |                 |     |
| Infection                      | 11 (15.1%) | 7 (17.9%)       | 4 (11.8%)       |     |
| Stress                         | 22 (30.1%) | 11 (28.2%)      | 11 (32.4%)      |     |
BMI: body mass index; VAS: visual analog scale; CDH: chronic daily headache; MOH: medication overuse headache; NDPH: new daily persistent headache

**Low education level**: illiteracy, elementary school and middle school;

**High education level**: high school, secondary vocational school, three-year college, a bachelor's degree and above.

### Table 2. Demographic and clinical characteristics between MOH and NDPH.

|                  | MOH (n=638) (%) | NDPH (n=73) (%) | p     |
|------------------|-----------------|-----------------|-------|
| **Sex, n**       |                 |                 | <0.001|
| Male             | 144 (22.6%)     | 39 (53.4%)      |       |
| Female           | 494 (77.4%)     | 34 (46.6%)      |       |
| **Age (years, mean±SD)** | 47.6±10.9 (48.0, 15.0) | 37.4±14.3 (35.0, 23.0) | <0.001|
| **Age at onset of CDH (years, mean±SD)** | 41.4±11.3 (41.0, 16.0) | 26.7±12.3 (23.0, 16.0) | <0.001|
| **Duration of CDH (years, mean±SD)** | 6.1±6.2 (4.0, 8.0) | 10.6±11.8 (5.0, 17.0) | 0.023|
| **Education level, n** |                 |                 | <0.001|
| Low education level | 345 (54.1%) | 19 (26.0%) |       |
| High education level | 293 (45.9%) | 54 (74.0%) |       |
| **Pain intensity (VAS, mean±SD)** | 6.9±1.6 (7.0, 2.0) | 5.3±2.0 (5.0, 2.0) | <0.001|

**Low level**: illiteracy, elementary school and middle school;

**High level**: high school, secondary vocational school, three-year college, a bachelor's degree and above.
Table 3. The relationship between therapeutic responses in patients with NDPH and demographic and clinical characteristics of these patients (n=62).

|                                     | Effective (n=31) | No effective (n=31) | p   |
|-------------------------------------|-----------------|---------------------|-----|
| **NDPH with trigger factors**       |                 |                     |     |
| n (%)                               | 20 (71.4%)      | 8 (28.6%)           | 0.002 |
| **NDPH without trigger factors**    |                 |                     |     |
| n (%)                               | 11 (32.4%)      | 23 (67.6%)          |     |
| **NDPH (6-24 months)**              |                 |                     |     |
| n (%)                               | 11 (68.8%)      | 5 (31.2%)           | 0.082 |
| **NDPH (>24 months)**               |                 |                     |     |
| n (%)                               | 20 (43.5%)      | 26 (56.5%)          |     |
| **Sex**                             |                 |                     | 0.80 |
| male                                | 17 (44.7%)      | 18 (55.3%)          |     |
| female                              | 14 (51.9%)      | 13 (48.1%)          |     |
| **Education level, n (%)**          |                 |                     | 0.78 |
| Low education level                 | 8 (47.1%)       | 9 (52.9%)           |     |
| High education level                | 23 (51.1%)      | 22 (48.9%)          |     |
| **Pain intensity** (years, median)  |                 |                     |     |
| VAS (mean±SD)                       | 4.9±1.6         | 4.9±1.8             | 0.78 |
| (years, median=quartiles)          | (5.0,2.0)       | (5.0,2.0)           |     |
| **Headache characteristics, n(%)**  |                 |                     | 0.25 |
| Like migraine                       | 10(62.5%)       | 6(37.5%)            |     |
| Like tension type headache          | 21(45.7%)       | 25(54.3%)           |     |

**BMI**: body mass index; **VAS**: visual analog scale; **NDPH**: new daily persistent headache; **Low level**: illiteracy, elementary school and middle school; **High level**: high school, secondary vocational school, three-year college, a bachelor’s degree and above.
Table 4. The relationship between therapeutic responses and different trigger factors of NDPH patients (n=28).

|                             | Effective (n=20) | No effective (n=8) | p    |
|-----------------------------|------------------|-------------------|------|
| NDPH with infection factor  | 3(37.5%)         | 5(62.5%)          | 0.002|
| n (%)                       |                  |                   |      |
| NDPH with stress factor     | 17(85.0%)        | 3(15.0%)          |      |
| n (%)                       |                  |                   |      |

**NDPH**: new daily persistent headache
Table 5. Demographic, clinical characteristics and triggering factors of patients with NDPH in different study.

| Study       | Diagnostic criteria | No. of patients | Female/male | Age of onset (years) | Prior headache history | Duration of headache (months) | Bilateral pain, n (%) | Throbbing Pain, n (%) | Pain intensity (VAS) | Aggravation by physical activities, n (%) | Associated feature | Nausea, n (%) | Vomiting, n (%) | Phonophobia, n (%) | Photophobia, n (%) | Medication overuse, n (%) | Psychiatric comorbidities |
|-------------|---------------------|-----------------|-------------|----------------------|------------------------|-------------------------------|-----------------------|----------------------|---------------------|-------------------------------------------------|---------------------|---------------|----------------|-------------------|-------------------|------------------------|---------------------------|
| Li[23] 2004 | S-L ICHD2           | 56              | 2.5         | 12-78 Med: 35.0      | 38%                    | >6 Range: 13-73               | 36(64)                | 31(55)               | 10(18)              | 18(32)                                                  | -                   | 38(68)        | 13(23)         | 34(61)            | 37(66)            | -                      | -                        |
| Takase[4] 2004 | ICHD2               | 30              | 0.8         | 28 Range: 8-76       | 7%                     | -                            | 26(87)                | 8(27)                | 34(61)              | 17(32)                                                  | -                   | 10(33)        | -              | -                 | -                 | -                      | -                        |
| Robbins[11] 2010 | M-ICHD2            | 71              | 2.5         | 28 Median: 43.1      | 25.4%                   | -                            | 63(88.7)              | 32(45.1)             | 34(61.9)            | 33(46.5)                                                  | -                   | 34(47.9)      | -              | -                 | -                 | -                      | -                        |
| Peng[13] 2011 | M-ICHD2            | 92              | 1.4         | 43.1 Range: 8-76     | 32%                    | -                            | 43(46.7)              | 38(41.3)             | 5.3                 | 53(57.6)                                                  | -                   | 32(34.8)      | -              | -                 | -                 | -                      | -                        |
| Prakash[12] 2012 | M-ICHD2            | 63              | 1.3         | 52(83) Mean: 27.5    | 54%                    | -                            | 52(83)                | 32(51)               | 16.9%               | 17(27)                                                  | -                   | 31(49)        | -              | -                 | -                 | -                      | -                        |
| Rozen[10] 2016 | ICHD-3β            | 97              | 2.0         | 52 Range: 18-68      | 41.2%                   | -                            | -                    | -                   | Mean: 7.5           | 9(16.4)                                                  | -                   | 31(56.4)      | 11(20)         | 12(16.4)          | 13(2)             | -                      | -                        |
| Uniyal[9] 2017 | ICHD-3β            | 55              | 0.8         | 45 Range: 6-61       | 38.2%                   | -                            | -                    | -                   | Mean: 5.3           | 32(43.8)                                                  | -                   | 14(19.2)      | 1(1.4)         | -                 | -                 | -                      | -                        |
| Current study | ICHD-3             | 73              | 0.9         | 58 Range: 13-58      | 1.4%                    | -                            | -                    | -                   | -                   | 12(16.4)                                                  | -                   | 13(2)        | -              | -                 | -                 | -                      | -                        |
|                      | reported | reported | reported | reported | reported | reported |
|----------------------|----------|----------|----------|----------|----------|----------|
| **Anxiety, n (%)**   | 24(33.8) | -        | 10(16)   | 51(92.7) | 38(52.1) |
| **Depression, n (%)**| 25(35.2) | 56(60.9) | 12(19)   | 49(89.1) | 27(36.9) |
| **Triggering factors** |          |          |          |          |          |          |
| **Infection/flu-like illness, n (%)** | 17(30) | a | 10(14.1) | 3(3.3) | 18(29) | 21(22) | 10(18) | 11(15.1) |
| **Stress, n (%)**    | 7(12) | 6(20) | 7(9.9) | 24(26.1) | 5(8) | 9(9) | 5(9.1) | 22(30.1) |
| **Trauma/surgery, n (%)** | 7(12) | a | - | - | 10(16) | 9(9) | 5(9.1) | - |
| **None, n (%)**      | >33% | 24(80) | 38(53.5) | 65(70.7) | 29(46) | 51(53) | 35(63.5) | 40(54.8) |
| **Other, n (%)**     | 6(8) | 9(14) | 7(7) | - |          |          |          |          |

**VAS:** visual analog scale; **NDPH:** new daily persistent headache; **S-L:** Silberstein-Lipton criteria;  
**ICHD:** International classification of headache disorders;  
**M-ICHD2:** Modified ICHD2 (NDPH according to the criteria A and B of the ICHD-2 regardless of the presence of migraine features.).  

\(^{a}\)Takase et al. excluded persistent headache occurred in relation to an infection or flu-like illness and headache after head and neck injury or surgery.